DiaMedica Inc. Completes Enrollment in Phase II Clinical Trial for DM-83

WINNIPEG, MANITOBA--(Marketwire - May 05, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces that it has enrolled the final patient in the phase II proof of concept clinical trial of DM-83.

Back to news